why choose us

First received: March 28, 2023

Clinical Trial: A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cryopyrin Associated Periodic Syndrome

Study Type: INTERVENTIONAL


Official Title: A Phase 2A, Single-Arm Study to Evaluate the Safety and Clinical Activity of VTX2735 in Participants With Cryopyrin-Associated Periodic Syndrome (CAPS)

Brief Summary: This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Cryopyrin-Associated Period Syndrome (CAPS).Approximately 10 patients will take VTX2735 Dose A or VTX2735 Dose B.The study consists of a screening/washout period of up to 28 weeks, a 2 week treatment period, a treatment withdrawal period of up to 2 weeks, another 2 week treatment period, and a 4 week follow up period.The maximum length of treatment is 4 weeks.

Read more